129791-92-0 Usage
Description
Rifalazil is an antimycobacterial agent that has been utilized in the treatment of tuberculosis as part of a multi-drug regimen. It is known for its effectiveness against Mycobacterium tuberculosis, the bacteria responsible for causing tuberculosis.
Uses
Used in Pharmaceutical Industry:
Rifalazil is used as an antimycobacterial agent for the treatment of tuberculosis. It is particularly effective against Mycobacterium tuberculosis, the bacteria that causes the disease. Its incorporation into a multi-drug regimen helps in managing and curing tuberculosis, a significant global health concern.
Used in Antimicrobial Applications:
Rifalazil is also used in the broader context of antimicrobial applications, specifically targeting mycobacterial infections. Its potent action against Mycobacterium species makes it a valuable addition to the arsenal of drugs used to combat drug-resistant tuberculosis strains, which pose a considerable challenge to public health.
Check Digit Verification of cas no
The CAS Registry Mumber 129791-92-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,2,9,7,9 and 1 respectively; the second part has 2 digits, 9 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 129791-92:
(8*1)+(7*2)+(6*9)+(5*7)+(4*9)+(3*1)+(2*9)+(1*2)=170
170 % 10 = 0
So 129791-92-0 is a valid CAS Registry Number.
InChI:InChI=1/C51H64N4O13/c1-24(2)23-54-16-18-55(19-17-54)32-21-33(57)39-35(22-32)67-48-40(52-39)36-37-44(60)30(8)47-38(36)49(62)51(10,68-47)65-20-15-34(64-11)27(5)46(66-31(9)56)29(7)43(59)28(6)42(58)25(3)13-12-14-26(4)50(63)53-41(48)45(37)61/h12-15,20-22,24-25,27-29,34,42-43,46,52,57-60H,16-19,23H2,1-11H3/b13-12+,20-15+,26-14-,53-41+/t25-,27-,28+,29-,34-,42-,43-,46+,51-/m0/s1
129791-92-0Relevant articles and documents
Preparation and in vitro anti-staphylococcal activity of novel 11-deoxy-11-hydroxyiminorifamycins
Li, Jing,Ma, Zhenkun,Chapo, Katrina,Yan, Dalai,Lynch, A. Simon,Ding, Charles Z.
, p. 5510 - 5513 (2008/03/13)
We report herein the preparation and anti-staphylococcal activity of a series of novel 11-deoxy-11-hydroxyiminorifamycins. Many of the compounds synthesized exhibit potent activity against wild-type Staphylococcus aureus with MICs equivalent to, or better
